Katherine B. Peters

Also affiliated with Duke Medical Center, Pediatric Brain Tumor Foundation

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168.v1

Top 100%

0DataRank

Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Papers

Driven by 17 papers — median percentile 0. Top paper: “Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial”.

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0611

N/A

4.8DataRank · unranked

264 citations

Marta Peñas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Jankú +16 more

Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment

Neuro-Oncology(2020)10.1093/neuonc/noaa105

N/A

1.7DataRank · unranked

52 citations

Robert J. Young, Benjamin M. Ellingson, Harini Veeraraghavan, Wei Wang, Florent Tixier +12 more

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network(2020)10.6004/jnccn.2020.0052

N/A

0.953DataRank · unranked

575 citations

Jana Portnow, Manmeet S. Ahluwalia, Joachim M. Baehring, Henry Brem, Steven Brem +30 more

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2500

N/A

0.835DataRank · unranked

261 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

Nature Medicine(2023)10.1038/s41591-022-02141-2

N/A

0.814DataRank · unranked

227 citations

Min Lu, Patrick Y. Wen, Jennie Taylor, Elizabeth A. Maher, Isabel Arrillaga-Romany +15 more

The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment

Neuro-Oncology Advances(2021)10.1093/noajnl/vdab035

N/A

0.724DataRank · unranked

14 citations

Quinn T. Ostrom, Shelley M. Pressley, Jennie Taylor, Alissa A. Thomas, Jeffrey S. Wefel +23 more

Long-term outcomes with reduced-dose whole-brain radiotherapy and a stereotactic radiosurgery boost for primary central nervous system lymphoma

Neuro-Oncology Advances(2023)10.1093/noajnl/vdad097

N/A

0.360DataRank · unranked

10 citations

Trey C. Mullikin, Scott Floyd, Chris R. Kelsey, Mallika Patel, Katherine B. Peters +4 more

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e14015

N/A

0.360DataRank · unranked

10 citations

Vidyalakshmi Chandramohan, Daniel Landi, Margaret Johnson, Mustafa Khasraw, Katherine B. Peters +12 more

Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2566

N/A

0.269DataRank · unranked

5 citations

Dina Randazzo, Vidyalakshmi Chandramohan, Katherine B. Peters, Margaret Johnson, Stevie Threatt +10 more

Neurocognitive outcomes in patients with brain metastases: a systematic review

The Lancet Oncology(2025)10.1016/s1470-2045(25)00525-x

N/A

0.269DataRank · unranked

5 citations

Sebastian Winter, Kristen A. Batich, Karin Gehring, Michael Parsons, Jörg Dietrich +13 more

New and Emerging Therapies for Patients with Low-Grade Glioma

CNS Drugs(2026)10.1007/s40263-025-01238-9

N/A

0.241DataRank · unranked

4 citations

Katherine B. Peters

DIET2TREAT: A randomized, multi-center, phase 2 trial of a ketogenic diet vs standard dietary guidance in combination with standard-of-care treatment for patients with newly diagnosed glioblastoma.

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.tps2103

N/A

0DataRank · unranked

1 citations

Gillian Gresham, Nicholas Butowski, Katherine B. Peters, Akanksha Sharma, Ekokobe Fonkem +10 more

CTNI-66. IDH-MUTANT GLIOMA PATIENTS TREATED WITH VORASIDENIB: ONGOING DATA FROM THE VORASIDENIB EXPANDED ACCESS PROGRAM

Neuro-Oncology(2024)10.1093/neuonc/noae165.0433

N/A

0DataRank · unranked

1 citations

Katherine B. Peters, Howard Colman, Jennie Taylor, Ingo K. Mellinghoff, Helen A. Shih +4 more

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168.v1

Top 100%

0DataRank

Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Seizure risk factors and management approaches in patients with brain metastases

Neuro-Oncology Practice(2025)10.1093/nop/npaf001

N/A

0DataRank · unranked

2 citations

Spencer M. Maingi, Kristen A. Batich, Sebastian Winter, Jörg Dietrich, Trey C. Mullikin +5 more

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168

Top 100%

0DataRank

Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.05.018

N/A

0DataRank · unranked

17 citations

Yi Ren, Yen P. Lowder, Sharareh Siamakpour‐Reihani, Sendhilnathan Ramalingam, Kristi Romero +45 more

Katherine B. Peters

Indexed papers

Top data-sharing exemplar

Papers